Medtronic Plc
(NYSE : MDT)

( )
MDT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
INOInovio Pharmaceuticals, Inc. 0.31%19.506.3%$556.03m
TMOThermo Fisher Scientific, Inc. 0.00%413.951.0%$526.19m
DHRDanaher Corp. 0.20%204.400.7%$487.30m
ABTAbbott Laboratories -0.06%100.640.8%$478.79m
ISRGIntuitive Surgical, Inc. 0.00%685.442.4%$474.16m
MDTMedtronic Plc -0.07%96.480.6%$441.79m
DXCMDexCom, Inc. 1.00%439.907.9%$424.36m
BDXBecton, Dickinson & Co. 0.00%281.341.0%$378.92m
BSXBoston Scientific Corp. -1.69%37.911.0%$338.03m
SYKStryker Corp. -0.06%193.301.3%$259.85m
ALGNAlign Technology, Inc. 0.06%293.996.3%$257.56m
BAXBaxter International, Inc. 0.01%86.381.8%$233.40m
QDELQuidel Corp. 1.64%287.107.7%$227.99m
EWEdwards Lifesciences Corp. -0.70%78.400.4%$224.84m
ZBHZimmer Biomet Holdings, Inc. 0.03%134.861.7%$169.85m

Company Profile

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.